Nucleai

Company Overview

Snapshot

Founded in July 2017 by Avi Veidman, Eliron Amir, and Lotan Chorev, Nucleai operates with 51–200 employees. The company has raised a total of $60.5 million across four funding rounds from 11 investors. In April 2024, Nucleai announced a strategic collaboration with GoPath Diagnostics to provide integrated AI-powered digital pathology solutions for clinical research and diagnostic applications.

Business overview

Nucleai develops a spatial biology software platform that leverages intelligence-grade geospatial AI methods to analyze and interpret complex cellular interactions in patient biopsies. This technology translates intricate biological data into actionable insights, accelerating the development of life-saving treatments and diagnostics. The platform offers a multimodal solution that ingests images from various modalities, conducts advanced spatial analysis, and delivers AI-powered data-rich action plans for pathologists and researchers. Nucleai serves the biopharma industry, working with over 60 percent of the top 20 biopharma companies globally, and partners with diagnostics, contract research organizations (CROs), and life sciences tools companies.

Strategic signal

In June 2024, Nucleai announced a partnership with Proscia to integrate predictive biomarker solutions, indicating a strategic move to enhance its AI-powered spatial biology analysis capabilities. This collaboration suggests a focus on expanding the utility of its platform within the precision medicine landscape, offering a stronger value proposition to biopharma partners seeking advanced diagnostic and treatment development tools.

Company Intelligence Q&A

What was a significant recent partnership for Nucleai?

In June 2024, Nucleai partnered with Proscia to integrate predictive biomarker solutions, aiming to enhance the capabilities of both companies in the digital pathology and precision medicine fields.

What recent operational change occurred at Nucleai?

In June 2024, Nucleai implemented workforce optimizations, resulting in a 15% reduction in its employee base.

What was the nature of Nucleai's collaboration with GoPath Diagnostics?

In April 2024, Nucleai and GoPath Diagnostics announced a strategic collaboration to provide integrated AI-powered digital pathology solutions for clinical research and diagnostic applications.

What was the focus of Nucleai's partnership with Lunaphore?

In September 2022, Lunaphore and Nucleai announced a partnership to provide AI-powered spatial biology analysis, aimed at accelerating drug development.